Christopher Burcham

Dr. Christopher Burcham is an Executive Director in the Synthetic Molecule Design and Development (SMDD) Department at Eli Lilly. Chris is currently responsible for the technical oversite and advancement of the spray drying and other enabling platforms. Prior to this he was the Scientific Team Leader for Reyvow™ (lasmiditan), a new selective serotonin 5-HT1F agonist, recently approved by the FDA for treatment of acute migraines in adults. As Scientific Team Leader, Chris was responsible for the technical oversight of all aspects of drug substance and drug product development, including process and product development, regulatory registration and technology transfer into Lilly Manufacturing Operations. Chris received his PhD from Princeton University in 1998, and his BS from the University of Illinois in 1992, both in Chemical Engineering. His career started at The Dow Chemical Company. In 2002, Chris joined Eli Lilly.